The North Star study is a multi-center, Phase 3, open-label, single-arm clinical study to evaluate the Efficacy and Safety of North Star therapy.
Diagnosed with primary hypothyroidism, including Hashimoto's Thyroiditis, and on therapy with a stable dose of LT4 (minimum 50 mcg per day, administered 7 days per week) for at least 12 weeks prior to Screening
Have had euthyroid status for at least 6 weeks and up to 12 months prior to Screening (Visit 1), with at least one documented minimum stable dose of 50 mcg LT4.
Agree to practice a method of contraception
Female patients not pregnant or lactating at Screening
Any clinical condition or previous surgery that might affect the absorption, distribution, biotransformation or excretion of North Star
Hospitalization for a major illness within 5 weeks prior to Screening
Concomitant use of prohibited medications or supplements
Have uncontrolled diabetes
Single group
Desiccated Porcine Thyroid Extract Tablets
DrugNorth Star
Thyroid-stimulating hormone (TSH) levels within the normal reference range at 24 weeks and at a prior post-baseline visit with no intervening out of range values
Collection and review of adverse events (AEs), serious adverse events (SAEs), suspected unexpected serious adverse reactions, adverse events of special interest, clinical laboratory evaluations, 12-lead ECG, and physical examination.
Safety will be evaluated by tracking the frequency, severity, and relationship of adverse events to the study drug from the first dose through the end of the follow-up period. The number and percentage of participants experiencing any treatment-emergent adverse event (TEAE) will be summarized by system organ class and preferred term. In addition, SAEs and TEAEs leading to withdrawal from the study will be summarized. Observed values and change from Baseline values in vital signs (body temperature, systolic and diastolic blood pressure, pulse, and respiratory rate), ECG parameters for QT interval evaluation, clinical laboratory parameters (hematology, serum chemistry, urinalysis) and physical examinations (to include general al appearance, head, eyes, ears, nose, throat, neck, cardiovascular, lungs, abdominal, extremities, neurologic, skin, lymph nodes, and musculoskeletal system) will be summarized by time point. All safety analyses will be based on the safety population.
Click on the lead sponsor to view all of their trials.
